G P Interglobe

G P Interglobe is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2013, the company is headquartered at 464, Udyog Vihar, Phase V, Gurugram, Haryana, India. It operates as a partnership firm under the Goods and Services Tax Network (GSTN) with the registration number 06AAMFG4678E1Z6. The company has a Legal Entity Identifier (LEI) of 335800LTLJXNN62SB351, indicating its active status in global financial markets. G P Interglobe's export activities are primarily focused on the advanced oncology therapeutic category, with a total export value of $114,000 USD across 14 shipments. The company's product portfolio is highly concentrated, with its top two products—Pembrolizumab and Daratumumab—accounting for 100% of its exports.

Specific details regarding G P Interglobe's manufacturing facilities, including their locations, capacities, and specializations, are not publicly available. The company's export data indicates a focus on advanced oncology formulations, suggesting that its manufacturing operations are likely tailored to produce specialized oncology drugs. However, without explicit information, a comprehensive assessment of their manufacturing capabilities cannot be provided.

Information about the key leadership of G P Interglobe, including the CEO, CFO, and other executives, is not publicly disclosed. The company's operations are managed by its partners, but specific names and roles are not available in the public domain. This lack of transparency makes it challenging to provide a detailed overview of the company's leadership structure.

G P Interglobe's export data indicates a focus on advanced oncology formulations, with Pembrolizumab and Daratumumab being its top two products. However, specific information regarding the company's regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan is not publicly available. The absence of such data suggests that G P Interglobe may not have established a significant presence in these regulated markets. Without explicit information, a comprehensive analysis of the company's standing in these regions cannot be provided.

G P Interglobe's export data does not specify its activities in emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus on advanced oncology formulations suggests potential opportunities in these regions, especially considering the increasing demand for specialized cancer treatments. However, without explicit information on the company's WHO prequalification status or other certifications, it is difficult to assess its ability to access these markets.

G P Interglobe's export data reveals a highly concentrated product portfolio, with its top two products—Pembrolizumab and Daratumumab—accounting for 100% of its exports. This concentration indicates a focused geographic strategy, likely targeting markets with high demand for advanced oncology treatments. However, the lack of detailed information on the company's geographic diversification and market presence makes it challenging to assess potential concentration risks or strategic direction.

Specific information regarding G P Interglobe's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The absence of such data suggests that the company may not have established a significant presence in the U.S. market or may not have pursued FDA approvals for its products. Without explicit information, a comprehensive assessment of the company's FDA status cannot be provided.

Information regarding G P Interglobe's WHO prequalification status, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The lack of such certifications may limit the company's ability to access certain international markets that require these standards. However, without explicit information, it is difficult to assess the impact of this on the company's operations.

G P Interglobe operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. Without access to this information, a comprehensive assessment of the company's compliance with Indian regulatory requirements cannot be provided.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to G P Interglobe. The absence of such data suggests that the company may not have faced significant regulatory challenges in its operations. However, without explicit information, it is difficult to assess the company's overall regulatory compliance history.

G P Interglobe's focus on advanced oncology formulations positions it in competition with other pharmaceutical companies specializing in oncology products. While specific market share data is not available, the company's export data indicates that Pembrolizumab and Daratumumab are its top two products, suggesting a competitive presence in the oncology market. However, without detailed information on competitors' offerings and market positions, a comprehensive competitive analysis cannot be provided.

G P Interglobe's specialization in advanced oncology formulations, particularly Pembrolizumab and Daratumumab, distinguishes it in the pharmaceutical export market. The company's focus on finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs, indicates a commitment to delivering ready-to-use products. However, without detailed information on the company's manufacturing capabilities and certifications, it is challenging to identify additional unique strengths or competitive advantages.

G P Interglobe's strategic direction appears to be focused on exporting advanced oncology formulations, with a concentrated product portfolio centered around Pembrolizumab and Daratumumab. The company's lack of diversification in its product offerings suggests a niche strategy targeting specific markets with high demand for these treatments. However, without explicit information on the company's future outlook and plans for expansion or diversification, a comprehensive assessment of its strategic position cannot be provided.

G P Interglobe's export data indicates a total export value of $114,000 USD across 14 shipments, with a product portfolio entirely concentrated on Pembrolizumab and Daratumumab. This suggests a focused approach to its export activities. However, the lack of detailed information on the company's manufacturing facilities, certifications, and regulatory compliance makes it challenging to assess its overall track record, export volume consistency, and reliability as a supplier.

Importers considering G P Interglobe as a supplier should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration (FDA) for sale in the U.S. market. This can be verified through the FDA's official website or by contacting the company directly.

• WHO-GMP Certification: Ensure that the company's manufacturing facilities comply with the World Health Organization's Good Manufacturing Practice (GMP) standards. This can be verified by checking the WHO's official website or by requesting certification documents from the company.

• EU GMP Certification: Verify that the company's manufacturing facilities meet the European Union's GMP standards. This can be confirmed through the European Medicines Agency (EMA) or by obtaining certification documents from the company.

• ISO Certification: Check for ISO certifications related to quality management systems, such as ISO 9001. These can be verified by requesting certification documents from the company or by checking with the International Organization for Standardization (ISO).

When considering G P Interglobe as a supplier, importers should undertake the following due diligence steps:

• Verify Regulatory Approvals: Confirm that the company's products have the necessary approvals from relevant regulatory bodies in the target market.

• Assess Manufacturing Capabilities: Evaluate the company's manufacturing facilities to ensure they meet required quality and safety standards.

• Review Financial Stability: Analyze the company's financial statements to assess its financial health and ability to fulfill orders.

• Check References and Reputation: Seek references from other clients and review the company's reputation in the industry.

• Inspect Product Quality: Request samples to assess the quality of the products offered.

Red flags to watch for include a lack of transparency in operations, absence of necessary certifications, and inconsistent product quality. Recommended pre-order checks involve verifying the company's compliance with regulatory standards, assessing the reliability of its supply chain, and ensuring that the products meet the required specifications.